# Characterization of Copy Number Variants in Hereditary Cancer Patients Through NGS Shows a Distinctive PALB2 Contribution to the Diagnostic Yield

**Authors:** Lia Bonamici, Lucia Artuso, Marco Marino, Angela Toss, Diletta Sidoti, Elena Barbieri, Marta Venturelli, Isabella Marchi, Chiara Pescucci, Rossella Manfredini, Laura Papi, Massimo Dominici, Laura Cortesi, Elena Tenedini, Enrico Tagliafico

PMC · DOI: 10.1155/humu/6601291 · Human Mutation · 2026-01-03

## TL;DR

This study shows that copy number variants in the PALB2 gene significantly contribute to cancer risk and are more common in certain geographic regions.

## Contribution

The study highlights the unique role of PALB2 CNVs in hereditary cancer and suggests a recent founder effect based on shared genetic patterns.

## Key findings

- CNVs were found in 1.4% of patients, with PALB2 showing the highest frequency of pathogenic CNVs.
- 24 out of 28 PALB2 CNV carriers shared a deletion in Exon 11, indicating a possible founder effect.
- Geographic origin and haplotype analysis suggest a recent origin for some PALB2 CNVs.

## Abstract

The extensive use of next‐generation sequencing (NGS) multi‐gene panels and advanced analysis algorithms have led to the identification of numerous genetic variants associated with breast, ovarian, and pancreatic cancer. Copynumber variations (CNVs), defined as deletions and duplications of specific DNA regions, account for up to 10% of pathogenic variants and can affect any of the cancer‐predisposing genes. Despite this, CNVs’ contribution beyond BRCA1 and BRCA2 remains underexplored. This observational study analyzed data from 2949 patients, primarily affected by breast or ovarian cancer, who underwent NGS testing with a 22‐gene hereditary cancer panel between 2018 and 2023, with a focus on CNV results. In line with comparison studies, a total diagnostic yield of 14.8% was observed with pathogenic variants in BRCA1, BRCA2, CHEK2, ATM, and PALB2 accounting for most of positive findings. In contrast, CNVs were found in 1.4% of patients, displaying a peculiar distribution pattern. PALB2 exhibited the highest frequency of pathogenic CNVs (66.7%), representing 62.2% of all PALB2 pathogenic variants. Notably, 24 out of 28 PALB2 CNV carriers shared the deletion of Exon 11. Further investigations revealed identical breakpoints and common geographical origins, and moreover, the same haplotype for some of the families suggests a relatively recent founder effect. Simultaneous sequence and copy number analyses resulted in likely higher positive predictive value of the test and, more interestingly, disclosed an unforeseen single contribution of CNVs in PALB2 gene, confirming geography as a key factor in shaping human genetic variations.

## Linked entities

- **Genes:** BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672], BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675], CHEK2 (checkpoint kinase 2) [NCBI Gene 11200], ATM (ATM serine/threonine kinase) [NCBI Gene 472], PALB2 (partner and localizer of BRCA2) [NCBI Gene 79728]
- **Diseases:** breast cancer (MONDO:0004989), ovarian cancer (MONDO:0005140), pancreatic cancer (MONDO:0005192)

## Full-text entities

- **Genes:** ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, CHEK2 (checkpoint kinase 2) [NCBI Gene 11200] {aka CDS1, CHK2, HuCds1, LFS2, PP1425, RAD53}, PALB2 (partner and localizer of BRCA2) [NCBI Gene 79728] {aka BROVCA5, FANCN, PNCA3}
- **Diseases:** cancer (MESH:D009369), CNV (MESH:D000092342), Hereditary Cancer (MESH:D009386), breast, ovarian, and pancreatic cancer (MESH:D010051), breast or ovarian cancer (MESH:D061325)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12759264/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12759264/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC12759264/full.md

---
Source: https://tomesphere.com/paper/PMC12759264